|No||1||Date of announcement||2020/11/02||Time of announcement||21:01:47|
|Subject||Oneness Biotech Co., LTD. receives a Mexican patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).|
To which item it meets
|paragraph 53||Date of events||2020/11/02|
1.Date of occurrence of the event:2020/11/02
2.Company name:ONENESS BIOTECH CO.,LTD.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Announcement of material information on cash capital increase by issuance of new shares for global depositary shares (GDSs).
(1) Total amount: USD 176,840,600
(2) Unit price: USD 51.11
(3) Units Issued:3,460,000 units issued, equivalent to 17,300,000common shares.
(4) Pricing Date:2020/10/27
(5) Issuance Date:2020/11/02
(6) Each GDS represents 5 common shares.
(7) Price per common share: TWD 292.39 (USD 1= TWD 28.604)
(8) Place of Listing:Luxembourg Stock Exchange.
(9) A specific person or persons are being contacted to subscribe through negotiation: None
(10)Funds utilization plan, and a statement of the expected benefits thereof: Funds raised from this offering will be used in research and development for accelerating milestone achievement.
(11)Impact on shareholders'equity: The dilution percentage by issuance of new shares for global depositary shares for the shareholding of existing shareholders is only 4.64 %. From the perspective of the financial structure of the company, this will increase our own funds for research and development as well as enhance our financial structure which will be beneficial to the company's future operating performance and global development.
7.Any other matters that need to be specified:
(1)Subscription by Employees:The agenda was approved by the Board of Directors on June 11th, 2020 in accordance with Article 267 of Company Act that ten percent (10%) of new shares issued under this cash capital increase shall be reserved for subscription by the employees of the company. The president has been authorized to have the reserved shares left unsubscribed by the employees be open for subscription by specific person or persons through negotiation or by issuing sponsored global depositary shares according to the issuance price.The number of shares subscribed through negotiation by Diamond Biofund Inc. is 1,300,000 shares, by Jing Ying Investment Co., Ltd. is 300,000 shares, and by Feng Sheng Investment Co., Ltd. 200,000 shares specific person or persons is 1,800,000 shares according to the issuance price.
(2)The payments from 17,300,000 share through issuance of common shares for participating global depository shares and 1,800,000 shares through negotiation with specific persons have been received on 2nd November 2020.
(3)The record date of capital increase is 2nd November 2020.